Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.61 |
| ▸ | RAB9A | P51151 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465394 | 0.90 | RAB9A (0.75) | MAPTRAB9ANPC1LMNAL3MBTL1 | |
| SCHEMBL5455899 | 0.89 | MAPT (0.53) | MAPTRAB9ANPC1LMNAL3MBTL1 | |
| SCHEMBL5549880 | 0.88 | MAPT (0.52) | MAPTRAB9ANPC1LMNAGAA | |
| SCHEMBL5550233 | 0.88 | RAF1 (0.55) | MAPTRAB9ANPC1LMNAL3MBTL1 | |
| SCHEMBL5453447 | 0.87 | MAPT (0.56) | MAPTRAB9ANPC1LMNAPABPC1 | |
| SCHEMBL5462720 | 0.86 | RAB9A (0.62) | MAPTRAB9ANPC1LMNAPABPC1 | |
| SCHEMBL5466109 | 0.82 | MAPT (0.57) | MAPTRAB9ANPC1LMNAL3MBTL1 | |
| SCHEMBL5453308 | 0.81 | GFER (0.53) | MAPTRAB9ANPC1LMNAPABPC1 | |
| SCHEMBL5465267 | 0.81 | TP53 (0.62) | MAPTRAB9ANPC1LMNAL3MBTL1 | |
| SCHEMBL5545068 | 0.80 | MAPT (0.55) | MAPTRAB9ANPC1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1764360-A1 | UREA DERIVATIVE | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249620-A1 | Urea Derivative | UGP2, SLC14A1, DGAT1 | MAPT 758/4885RAB9A 1528/4885NPC1 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.